celecoxib + fluorouracil + leucovorin + oxaliplatin (Cancer and Leukemia Group B)

Celecoxib + fluorouracil + leucovorin + oxaliplatin is a combination chemotherapy and targeted therapy regimen investigated for the adjuvant treatment of resected stage III colon cancer. The regimen adds celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, to the standard-of-care FOLFOX chemotherapy backbone, which consists of the antimetabolite fluorouracil, the biochemical modulator leucovorin, and the platinum-based alkylating agent oxaliplatin. Celecoxib is intended to inhibit the COX-2 enzyme, which is frequently overexpressed in colorectal tumors and associated with inflammation-mediated tumor growth and proliferation. This specific combination was the focus of the large-scale Phase III CALGB/SWOG 80702 trial conducted by the Alliance for Clinical Trials in Oncology. While the primary analysis of the trial did not show a statistically significant improvement in disease-free survival for the overall population, the regimen remains a subject of research regarding potential benefits in specific molecular subgroups, such as those with PIK3CA mutations or detectable circulating tumor DNA (ctDNA).

Other names

FOLFOX plus celecoxibcelecoxib and FOLFOXCelecoxib and FOLFOX in Resected Stage III Colon Cancer